AIA. Insunza

A. Insunza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. Insunza has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Implementation of a strategy to prevent TRALI in a regional blood centre

    by A. Insunza, I. Romon, M. L. Gonzalez‐Ponte, A. Hoyos, J. M. Pastor, A. Iriondo, V. Hermosa

    summary Transfusion‐related acute lung injury (TRALI) can be a life‐threatening complication of transfusion and it is probably underdiagnosed. Human leucocyte antigen (HLA) and granulocyte antibodies are thought to play a major role, but preventive measures are difficult to implement. In our regional blood centre, we implemented a preventive strategy avoiding donor deferral. Previously, pregnant apheresis donors were screened for HLA antibodies, and those with positive results were assigned to a plasma‐only protocol. Plasma from these donors and from all previously pregnant whole blood donors was diverted for protein fractionation. Plasma‐poor red blood cells (in additive solution, buffy coat removed) and platelets (pools with additive solution) were prepared. Prestorage leucodepletion was also applied.We found HLA antibodies in 18·1% of previously pregnant apheresis donors, and our strategy caused a 6·0% loss of apheresis platelets, a 4·8% increase of apheresis fresh frozen plasma (FFP) and a 7·8% loss of transfusable apheresis FFP. The effect on FFP from whole blood donors could be compensated. The platelet preparation method reduced the mean volume of plasma from each donor to 24·4 mL. Fifteen months after the start of our strategy, no cases of TRALI have been reported. Our experience shows that a practical strategy to prevent TRALI is feasible.


    • 1 February 1995
      • Vol. 40  (1) , 25-37

    [Infective complications in bone marrow transplantation].

    by E Conde, M J Rabuñal, C Richard, M Tapia, J Baro, I Romón, A Iriondo, A Insunza, E Bureo, I Olalla

    • 1 September 1993
      • Vol. 12  (3) , 237-41

    Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome.

    by C Richard, I Romón, J Baro, A Insunza, I Loyola, F Zurbano, M Tapia, A Iriondo, E Conde, A Zubizarreta

    Eight patients with acute leukemia (AL) and invasive pulmonary aspergillosis (IPA) developing during previous antileukemic therapy underwent BMT (autologous in 6 cases and allogeneic 2). IPA was treated prior to BMT with full doses of amphotericin B, associated with surgical resection in three cases. One patient was treated with amphotericin B and itraconazole. Prior to BMT, seven patients had minimal residual pulmonary lesions. All patients received amphotericin B (0.5 mg/kg/day) during the aplastic period prior to engraftment. One patient died of Gram-negative septic shock before engraftment. Seven patients achieved complete hematological engraftment without any evidence of IPA reactivation. Amphotericin B was well tolerated with only minimal transient renal dysfunction in three patients. Later pulmonary complications related to IPA were observed in only one patient who developed a self-limited episode of hemoptysis. One patient died of CMV pneumonitis and two of leukemia relapse. Four patients survive disease-free and without complications related to IPA. We conclude that the reactivation of correctly treated IPA can be successfully prevented in BMT patients by use of prophylactic amphotericin B. With this approach, prior IPA is not a contraindication to BMT.